Unlock instant, AI-driven research and patent intelligence for your innovation.

Formulations of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide

A technology of dimethylphenyl and thiophene carboxamide, which is applied in anti-inflammatory agents, pill delivery, non-central analgesics, etc., and can solve problems such as long-term storage

Inactive Publication Date: 2011-07-27
ENCYSIVE PHARMA INC
View PDF119 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Contains N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thienyl Amide formulations may require prolonged storage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Formulations of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide
  • Formulations of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide
  • Formulations of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0102] N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide preparation of

[0103] Step 1: Preparation of compound 1:

[0104]

[0105] To a 250 mL round bottom flask equipped with a magnetic stir bar was added 20.0 gm 5-amino-3,4-dimethylisoxazole, 50 mL pyridine and 2.0 gm (catalytic amount) dimethylaminopyridine. While adding 21.5 gm of 2-carboxymethyl-3-thiophenesulfonyl chloride in portions, the mixture was cooled in an ice bath. The flask was sealed, the ice bath was removed, and the reaction was allowed to stir at room temperature overnight. Most of the pyridine was removed by rotary evaporation and the residue was partitioned between ethyl acetate and 2N HCl. The layers were separated and the aqueous layer was extracted with ethyl acetate (2X). The combined extracts were washed with dilute HCL (2X), brine (2X), and dried over magnesium sulfate. Filtration and concentration by rotary evaporation yielded 23.2 gm o...

Embodiment 2

[0122] N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide preparation of

[0123]

[0124] At 0°C: To 1.6 g of 60% NaH in mineral oil was added a solution of 1.12 g of the compound of formula (III) in 10 ml of DMF. After stirring for 15 minutes, a solution of 3.35 g of the compound of formula (II) in 10 ml of DMF was added dropwise. The reaction was stirred for 2 hours, followed by the slow addition of 50 ml 2N HCl (caution, excess NaH). The resulting suspension was extracted with toluene (4x25ml). The organic layers were combined and washed with 2N HCl (4x25ml) hydrochloric acid, followed by saturated NaHCO 3 (4x10ml) extraction. The bicarbonate layers were combined and acidified with concentrated HCl to pH ~1-2 and extracted with EtOAc (3x25ml). The EtOAc layers were combined and washed with 2N HCl (25ml), 2N HCl / brine (25ml), washed over MgSO 4 Drying and concentration in vacuo yielded 4.0 g of N-(2-acetyl-4,6-dime...

Embodiment 2a

[0125] Embodiment 2a: the preparation of formula (II) compound

[0126]

[0127] To a solution of 5.7 g of compound of formula (IV) in 60 ml of EtOAc was added 3.1 g of CDI. After stirring for 4 hours, the reaction mixture was concentrated in vacuo. Crystallization from hot EtOAc afforded 4.25 g of compound of formula (II) as >99% white solid by HPLC. 1 H NMR (400MHz, CDCl 3 ): δ2.40(s, 3H), 2.43(s, 3H), 2.53(s, 3H), 7.35(brs, 1H), 7.41(d, J=5.1Hz, 1H), 7.45(brs, 1H) and 7.91 (d, J = 5.1 Hz, 1H) ppm. MS(ESI)m / z: 693.08[2M+H] + , and 336.00[M+H] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Osmotic pressureaaaaaaaaaa
Hardnessaaaaaaaaaa
Login to View More

Abstract

Provided herein are intravenous and oral formulations of N-(2-acetyl-4,6-dimethylphenyl)-3 -{ [(3,4 dimethyl-5 -isoxazolyl)amino] sulfonyl }-2-thiophenecarboxamide. Also provided are methods of making and using the formulations.

Description

[0001] priority claim [0002] This application claims priority to US Provisional Application 60 / 937,215, filed June 25, 2007, by Chen et al. The disclosure content of the above-mentioned application is incorporated by reference in its entirety. technical field [0003] Provided herein is N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl}-2- Thiophene carboxamide formulations and methods of using the formulations to treat disorders mediated by endothelin. In certain embodiments, provided herein are intravenous (IV) formulations. In certain embodiments, the formulation is an oral tablet. Also provided are methods of making and using the formulations. Background technique [0004] N-(2-acetyl-4,6-dimethylphenyl)-3-([(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide Regulates the activity of peptides of the endothelin family and is useful in the treatment of disorders mediated by endothelin. Contains N-(2-acetyl-4,6-dimethylpheny...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/08A61K9/20A61K31/422
CPCA61K31/422A61K9/2009A61K9/0019A61P1/00A61P11/06A61P13/12A61P15/00A61P15/08A61P17/02A61P27/02A61P29/00A61P43/00A61P9/00A61P9/12A61K9/20A61K9/08
Inventor 陈金玲利安·拉朱斯基阿伦·舍尼曼安德鲁·特拉梅尔肯特·阿姆斯伯里
Owner ENCYSIVE PHARMA INC